Home Cart Sign in  
Chemical Structure| 1338545-07-5 Chemical Structure| 1338545-07-5

Structure of OTS964 HCl
CAS No.: 1338545-07-5

Chemical Structure| 1338545-07-5

OTS964 HCl

CAS No.: 1338545-07-5

OTS-964 is aTOPK (T-LAK cell originated protein kinase) inhibitor with IC50 value of 28 nM, which can specifically block cytokinesis, leading to apoptosis, in a broad range of cancer cells.

Synonyms: OTS-964; OTS964 (hydrochloride); OTS964 hydrochloride

4.5 *For Research Use Only !

Cat. No.: A217615 Purity: 99%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łËʶÊÊ Inquiry Inquiry
2mg łËÿ¶ÊÊ Inquiry Inquiry
25mg łóÿ¶ÊÊ Inquiry Inquiry
50mg łÇͧ¶ÊÊ Inquiry Inquiry
100mg łËÍͶÊÊ Inquiry Inquiry
250mg łÍÇò¶ÊÊ Inquiry Inquiry
1g łÇÇ˧¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • 1mg

    łËʶÊÊ

  • 2mg

    łËÿ¶ÊÊ

  • 25mg

    łóÿ¶ÊÊ

  • 50mg

    łÇͧ¶ÊÊ

  • 100mg

    łËÍͶÊÊ

  • 250mg

    łÍÇò¶ÊÊ

  • 1g

    łÇÇ˧¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of OTS964 HCl

CAS No. :1338545-07-5
Formula : C23H25ClN2O2S
M.W : 428.97
SMILES Code : O=C1NC2=C(C(C3=CC=C([C@@H](C)CN(C)C)C=C3)=C(O)C=C2C)C4=C1SC=C4.[H]Cl
Synonyms :
OTS-964; OTS964 (hydrochloride); OTS964 hydrochloride
MDL No. :MFCD28386220
InChI Key :YHPWOYBWUWSJDW-UQKRIMTDSA-N
Pubchem ID :89675898

Safety of OTS964 HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of OTS964 HCl

MAPK

Isoform Comparison

Biological Activity

Target
  • TOPK

    TOPK, IC50:28 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
H1299 200 nM 4-hour pretreatment, washed off after 24 hours PMC5558685
T24 200 nM 4-hour pretreatment, washed off after 24 hours Evaluate migration capacity PMC5558685
HeLa 100 nM 4-hour pretreatment, washed off after 24 hours PMC5558685
HCT116 70 nM 4-hour pretreatment, washed off after 24 hours PMC5558685
PC3 200 nM 4-hour pretreatment, washed off after 24 hours Evaluate the inhibitory effect of TH287 on 8-oxodGTPase activity PMC5558685
SQ20B 200 nM 4-hour pretreatment, washed off after 24 hours To evaluate the radiosensitizing effect of OTS964 on SQ20B cells, showing SER10 of 1.54 (P=0.003). PMC5558685
DU145 70 nM 4-hour pretreatment, washed off after 24 hours To evaluate the effect of SAHA and veliparib alone or in combination on cell viability. Results showed that co-treatment significantly decreased cell viability. PMC5558685
Calu-6 lung cancer cells 20 nM 24 hours To evaluate the radiosensitizing effect of OTS964 on Calu-6 cells, results showed that OTS964 significantly increased radiosensitivity. PMC8027845
H460 lung cancer cells 20 nM 24 hours To evaluate the radiosensitizing effect of OTS964 on H460 cells, results showed that OTS964 significantly increased radiosensitivity. PMC8027845
DLD-1 cells 1 μM 8 hours To evaluate the effect of E7449 on Wnt signaling, results showed increased axin2 protein levels. PMC9477540
MIA PaCa-2 cells 100 nM 72 hours Bestatin inhibited anchorage-independent growth of MIA PaCa-2 cells, but the effect was less significant than resveratrol PMC9477540
A375 cells 100 nM 10 hours PLX51107 combined with BRAFi/MEKi significantly inhibited the growth of A375 cells and reduced S-phase entry. PMC9477540
HUVEC cells 128 ng/mL 72 hours To assess the biocompatibility of PP@T, results showed that even at higher concentrations, the viability of HUVEC cells remained above 85%. PMC9318418
B16F0 cells 64 ng/mL 24 hours Evaluate the cytotoxicity of OTS964 on B16F0 cells, showing significant inhibition of cell growth PMC9318418
A375 cells 100 nM 12 days PLX51107 combined with BRAFi/MEKi significantly inhibited the growth of A375 cells and reduced S-phase entry. PMC9722545

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
CD-1 nude mice H460 and Calu-6 lung cancer xenograft models Intraperitoneal injection 20 mg/kg Administered on days 0 and 2 To evaluate the effect of OTS964 in combination with fractionated radiotherapy, results showed that OTS964 significantly delayed tumor growth. PMC8027845
Mice B16F0 tumor model Intraperitoneal injection 1 mg/kg Every 2 days, total 3 times Evaluate the antitumor effect of OTS964 in vivo, showing significant tumor growth inhibition PMC9318418

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.33mL

0.47mL

0.23mL

11.66mL

2.33mL

1.17mL

23.31mL

4.66mL

2.33mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories